Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

NET 4Endocrine 4Gastrointestinal 2Other neoplasm 1

Conditions

Neuroendocrine Tumors 3Gastro-enteropancreatic neuroendocrine tumor 1Digestive System Neuroendocrine Tumor G1 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 41Everolimus 38Magnetic Resonance Spectroscopy 18Temozolomide 17lanreotide 16gallium Ga 68 dotatate 15Octreotide 14pembrolizumab 13Nivolumab 13Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11surufatinib 9pasireotide 9Sunitinib 9Specimen Handling 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Lutetium-177 8Carboplatin 8amino-acid, glucose, and electrolyte solution 6Ipilimumab 6Ga(III)-DOTATOC 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5copper dotatate CU-64 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × 64Cu-DOTATATE × NET × Clear all
NCT06122610 2026-05-15

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

University of Wisconsin, Madison

Phase 1 Recruiting
10 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT06016855 2025-12-17

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Vanderbilt-Ingram Cancer Center

Phase 4 Recruiting
6 enrolled
EndocrineGastrointestinalNETOther neoplasm

Digestive System Neuroendocrine Tumor G1

NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03673943 2022-12-22

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Radiomedix, Inc.

Phase 3 Completed
63 enrolled 8 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡